N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl
- PMID: 2542016
- PMCID: PMC400826
- DOI: 10.1002/j.1460-2075.1989.tb03397.x
N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl
Abstract
The two major forms of the c-abl gene differ from their activated counterpart, the v-abl oncogene of the Abelson murine leukemia virus by the replacement of their N-terminal sequences with viral gag sequences. Overexpression of p150c-abl type IV in a retroviral vector similar to Abelson virus does not transform NIH 3T3 fibroblasts, even though it is expressed and myristoylated at levels comparable to pp160v-abl. Members of a nested set of deletion mutations of the N-terminus of c-abl type IV in this expression system will activate abl to transform murine fibroblasts. The smallest of these deletions, delta XB, efficiently transforms lymphoid cells in vitro and causes leukemia in vivo demonstrating that gag sequences are not necessary for abl-induced leukemogenesis. The delta XB mutation defines an N-terminal regulatory domain, which shares a surprising homology with chicken oncogene v-crk and phospholipase C-II. Although overexpression of the myristoylated form of c-abl does not transform cells, it nonetheless has a profound effect on cell growth.
Similar articles
-
Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.Proc Natl Acad Sci U S A. 1990 Sep;87(17):6502-6. doi: 10.1073/pnas.87.17.6502. Proc Natl Acad Sci U S A. 1990. PMID: 2168550 Free PMC article.
-
bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation.Mol Cell Biol. 1990 Aug;10(8):4365-9. doi: 10.1128/mcb.10.8.4365-4369.1990. Mol Cell Biol. 1990. PMID: 2164639 Free PMC article.
-
Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.EMBO J. 1989 Jan;8(1):137-47. doi: 10.1002/j.1460-2075.1989.tb03358.x. EMBO J. 1989. PMID: 2496972 Free PMC article.
-
Activation of the abl oncogene and its involvement in chromosomal translocations in human leukemia.Mutat Res. 1988 May;195(3):231-43. doi: 10.1016/0165-1110(88)90002-4. Mutat Res. 1988. PMID: 3129652 Review.
-
Structures and activities of activated abl oncogenes.Curr Top Microbiol Immunol. 1989;147:129-53. doi: 10.1007/978-3-642-74697-0_4. Curr Top Microbiol Immunol. 1989. PMID: 2695292 Review. No abstract available.
Cited by
-
Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization.Mol Cell Biol. 2000 Feb;20(3):741-8. doi: 10.1128/MCB.20.3.741-748.2000. Mol Cell Biol. 2000. PMID: 10629029 Free PMC article.
-
3BP-1, an SH3 domain binding protein, has GAP activity for Rac and inhibits growth factor-induced membrane ruffling in fibroblasts.EMBO J. 1995 Jul 3;14(13):3127-35. doi: 10.1002/j.1460-2075.1995.tb07315.x. EMBO J. 1995. PMID: 7621827 Free PMC article.
-
Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.Mol Cell Biol. 1994 May;14(5):2883-94. doi: 10.1128/mcb.14.5.2883-2894.1994. Mol Cell Biol. 1994. PMID: 8164650 Free PMC article.
-
Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition.J Transl Med. 2024 May 7;22(1):431. doi: 10.1186/s12967-024-05150-6. J Transl Med. 2024. PMID: 38715059 Free PMC article.
-
A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.Mol Cell Biol. 1992 Mar;12(3):1312-23. doi: 10.1128/mcb.12.3.1312-1323.1992. Mol Cell Biol. 1992. PMID: 1545812 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous